Literature DB >> 8396089

Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses.

D Girard1, J M Bergeron, W B Milisen, J A Retsema.   

Abstract

During the process of abscess formation, a myriad of changes are observed histologically that impede the penetration of antimicrobial agents into infection loci. A Staphylococcus aureus foreign body abscess, developed in rats, was employed to evaluate the penetration kinetics of azithromycin, roxithromycin and cephalexin at various stages of abscess development; the progressive patho-histological changes of abscess formation were also characterized in this model. In an early abscess (18 h post-challenge), azithromycin penetration into inflammatory fluid was enhanced (AUC of 351 vs 130 mg.h/kg) and residence prolonged relative to an inflammation control (half-life of 88 vs 27 h). In contrast, roxithromycin and cephalexin penetration into, and residence in, inflammatory fluid were unaltered in the early abscess. However, penetration into, and egress from, a mature abscess (ten days post-challenge) were impeded for all three antimicrobials (P < or = 0.03). The penetration kinetics of azithromycin into inflammatory fluid in an early abscess were independent of the dose regimen, but dependent on the total dose. The persistently high concentrations of azithromycin in inflammatory fluid within abscess were associated with the infiltration of phagocytic cells and encapsulation by fibrous tissue. These data are consistent with a phagocytic delivery mechanism for azithromycin, whereby the presence of high concentrations of azithromycin in inflammatory fluid are a consequence of augmented drug distribution via the release of accumulated intracellular drug from the infiltrating phagocytic cells and fibroblasts associated with abscess formation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396089     DOI: 10.1093/jac/31.suppl_e.17

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  In vitro evaluation of polyethylene glycol based microparticles containing azithromycin.

Authors:  Shunmugaperumal Tamilvanan; Vinay Kumar; Deepak Sharma; Ashutosh Thakur
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

2.  Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen.

Authors:  Ping Liu; Hameed Allaudeen; Richa Chandra; Kem Phillips; Arvid Jungnik; Jeanne D Breen; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin.

Authors:  Richa Chandra; Ping Liu; Jeanne D Breen; Jeannine Fisher; Charles Xie; Robert LaBadie; Rebecca J Benner; Lisa J Benincosa; Amarnath Sharma
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.

Authors:  J G den Hollander; J D Knudsen; J W Mouton; K Fuursted; N Frimodt-Møller; H A Verbrugh; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

6.  Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media.

Authors:  N Principi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

Review 7.  Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria.

Authors:  R J Kothavade; R S Dhurat; S N Mishra; U R Kothavade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-09       Impact factor: 3.267

8.  Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.

Authors:  Mitchell H Friedlaender; Eugene Protzko
Journal:  Clin Ophthalmol       Date:  2007-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.